Pour savoir comment effectuer et gérer un dépôt de document, consultez le « Guide abrégé – Dépôt de documents » sur le site Web de la Bibliothèque. Pour toute question, écrivez à corpus@ulaval.ca.
 

Personne :
Calon, Frédéric

En cours de chargement...
Photo de profil

Adresse électronique

Date de naissance

Projets de recherche

Structures organisationnelles

Fonction

Nom de famille

Calon

Prénom

Frédéric

Affiliation

Université Laval. Faculté de pharmacie

ISNI

ORCID

Identifiant Canadiana

ncf11850589

person.page.name

Résultats de recherche

Voici les éléments 1 - 2 sur 2
  • PublicationAccès libre
    Spray and freeze drying of human milk on the retention of immunoglobulins (IgA, IgG, IgM)
    (M. Dekker, 2016-03-07) Castro-Albarràn, Jorge; St-Amour, Isabelle; Aguilar-Uscanga, Blanca Rosa; Calon, Frédéric; Saucier, Linda; Solís-Pacheco, Josué; Ratti, Cristina
    Several freeze-drying and spray-drying methods were investigated in relation to the retention of immunoglobulins (Ig) A, IgG, and IgM. Spray drying produced human milk powders with 2% humidity and a good retention of IgG (>88%) and IgM (∼70%). However, only 38% of IgA remained after spray drying. For freeze drying, only the highest heating plate temperature used in this study (40°C) brought IgA content down to 55% in powder with 1.75% residual humidity, whereas milk samples undergoing lower temperatures had higher preservation rates (75% for IgA and 80% for IgG and IgM) and higher residual moisture contents. From these results, it can be concluded that IgA is the most sensitive Ig lost during drying processing of human milk. The best method to generate human milk powders without a significant loss of Ig was thus freeze drying at 30°C heating plate temperature, which accelerated the process compared to lower processing temperatures, but still had good overall Ig retention.
  • PublicationRestreint
    Cystamine metabolism and brain transport properties : clinical implications for neurodegenerative diseases
    (Wiley, 2010-06-20) Bousquet, Mélanie; Calon, Frédéric; Gibrat, Claire; Rouillard, Claude; Cicchetti, Francesca; Ouellet, Mélissa
    Cystamine has shown significant neuroprotective properties in preclinical studies of Parkinson’s disease (PD) and Huntington’s disease (HD). Cysteamine, its FDA-approved reduced form, is scheduled to be tested for clinical efficacy in HD patients. Here, we studied the key cystamine metabolites, namely cysteamine, hypotaurine and taurine, as well as cysteine, in order to identify which one is more distinctively responsible for the neuroprotective action of cystamine. After a single administration of cystamine (10, 50 or 200 mg/kg), naïve mice were perfused with phosphate-buffered saline (PBS) at 1, 3, 12, 24 or 48 h post-injection and brain and plasma samples were analyzed by two distinct HPLC methods. Although plasma levels remained under the detection threshold, significant increases in cysteamine brain levels were detected with the 50 and 200 mg/kg doses in mice perfused 1 and 3 h following cystamine injection. To further assess cysteamine as the candidate molecule for pre-clinical and clinical trials in PD, we evaluated its capacity to cross the blood brain barrier. Using an in situ cerebral perfusion technique, we determined that the brain transport coefficient (Clup) of cysteamine (259 μM) was 0.15 ± 0.02 μL/g/s and was increased up to 0.34 ± 0.07 μL/g/s when co-perfused in the presence of cysteine. Taken together, these results strongly suggest that cysteamine is the neuroactive metabolite of cystamine and may further support its therapeutic use in neurodegenerative diseases, particularly in HD and PD.